Talk:Masitinib

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Masitinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Phase 3 clinical trial for alzheimers due to complete in 2017 ?

Latest comment: 7 years ago1 comment1 person in discussion

According to [1] p4 its due to complete in 2017 - need RS eg CT.gov but [2] hasn't been updated. What do AB science say ? - Rod57 (talk) 12:36, 25 July 2017 (UTC)Reply

poorly phrased intro

Latest comment: 1 year ago1 comment1 person in discussion

the drug is not approved for humans see the drug companies owwn website https://www.ab-science.com/pipeline/ — Preceding unsigned comment added by 50.245.17.105 (talk) 15:05, 3 February 2023 (UTC)Reply

Add topic